VDPHL-01

DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages.

Veradermics has launched a nationwide Phase 2/3 clinical trial for VDPHL01, a promising non-hormonal oral treatment for androgenetic alopecia, backed by a $75 million funding round.

Veradermics Inc., a New Haven-based biopharmaceutical company, has successfully closed a $75 million Series B financing round. The funding, led by Suvretta Capital Management with participation from new and existing investors, will support ongoing clinical trials for VDPHL01, an investigational medicine for androgenetic alopecia (AGA), also known as pattern hair loss.